Statins: have we found the Holy Grail?

被引：12

作者：

Jeger, Raban ^{[1
]}

Dieterle, Thomas ^{[1
]}

机构：

[1] Univ Hosp, CH-4031 Basel, Switzerland

来源：

SWISS MEDICAL WEEKLY | 2012年 / 142卷

关键词：

statin; cardiovascular disease; hypercholesterolaemia; HMG-COA REDUCTASE; PRIMARY PREVENTION; CARDIOVASCULAR-DISEASE; CLINICALLY RELEVANT; LDL CHOLESTEROL; THERAPY; RISK; METAANALYSIS; MORTALITY; SIMVASTATIN;

D O I：

10.4414/smw.2012.13515

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

In coronary artery disease, cardiovascular risk factors are the main targets for primary and secondary prevention. Statins prevent cardiovascular events in patients at risk. However, despite the proven efficacy and safety of statins, relevant side effects exist and should be considered when treating patients.

引用

页数：4

共 31 条

[1]

Allender S., 2008, EUROPEAN CARDIOVASCU

[2] EFFECTS OF LOVASTATIN THERAPY ON VERY-LOW-DENSITY LIPOPROTEIN TRIGLYCERIDE-METABOLISM IN SUBJECTS WITH COMBINED HYPERLIPIDEMIA - EVIDENCE FOR REDUCED ASSEMBLY AND SECRETION OF TRIGLYCERIDE-RICH LIPOPROTEINS [J].

ARAD, Y ;

RAMAKRISHNAN, R ;

GINSBERG, HN .

METABOLISM-CLINICAL AND EXPERIMENTAL, 1992, 41 (05) :487-493

[3] The safety of statins in clinical practice [J].

Armitage, Jane .

LANCET, 2007, 370 (9601) :1781-1790

[4] Intensive lowering of LDL cholesterol with 80 mg versus 20 mg simvastatin daily in 12 064 survivors of myocardial infarction: a double-blind randomised trial [J].

Armitage, Jane ;

Bowman, Louise ;

Wallendszus, Karl ;

Bulbulia, Richard ;

Rahimi, Kazem ;

Haynes, Richard ;

Parish, Sarah ;

Peto, Richard ;

Collins, Rory ;

Meade, T. ;

Sleight, P. ;

Collins, R. ;

Armitage, J. ;

Bowman, L. ;

Parish, S. ;

Peto, R. ;

Barton, J. ;

Bray, C. ;

Wincott, E. ;

Dayanandan, R. ;

Clarke, R. ;

Graham, I. ;

Simpson, D. ;

Warlow, C. ;

Wilken, D. ;

Tobert, J. ;

Mushner, T. ;

Doll, R. ;

Wilhelmsen, L. ;

Fox, K. ;

Hill, C. ;

Sandercock, P. ;

Webster, J. ;

Henderson, J. ;

Nixon, A. ;

Lackie, S. ;

Thompson, J. ;

Brown, M. ;

Blackwood, S. ;

Morgan, M. ;

Rhoden, W. ;

Saeed, B. ;

Houghton, M. ;

Nicholson, A. ;

Simpson, C. ;

Hoburn, B. ;

Cooper, I. ;

Gallivan, A. ;

Pickerell, E. ;

Hancock, J. .

LANCET, 2010, 376 (9753) :1658-1669

[5] Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials [J].

Baigent, C. ;

Blackwell, L. ;

Emberson, J. ;

Holland, L. E. ;

Reith, C. ;

Bhala, N. ;

Peto, R. ;

Barnes, E. H. ;

Keech, A. ;

Simes, J. ;

Collins, R. .

LANCET, 2010, 376 (9753) :1670-1681

[6] Reduced thrombus burden with abciximab delivered locally before percutaneous intervention saphenous vein grafts [J].

Barsness, GW ;

Buller, C ;

Ohman, M ;

Schechter, E ;

Pucillo, A ;

Taylor, MA ;

Miller, MJ ;

Reiner, JS ;

Churchill, D ;

Chandler, AB ;

Gonzalez, M ;

Smith, J ;

Tommaso, C ;

Berdan, LG ;

Wildermann, NM ;

Hasdai, D ;

Holmes, DR .

AMERICAN HEART JOURNAL, 2000, 139 (05) :824-829

[7] Statin effects beyond lipid lowering-are they clinically relevant? [J].

Bonetti, PO ;

Lerman, LO ;

Napoli, C ;

Lerman, A .

EUROPEAN HEART JOURNAL, 2003, 24 (03) :225-248

[8]

BROWN MS, 1980, J LIPID RES, V21, P505

[9] Are the effects of statins on HDL-cholesterol clinically relevant? [J].

Chapman, MJ .

EUROPEAN HEART JOURNAL SUPPLEMENTS, 2004, 6 (0C) :C58-C63

[10] Estimation of ten-year risk of fatal cardiovascular disease in Europe:: the SCORE project [J].

Conroy, RM ;

Pyörälä, K ;

Fitzgerald, AP ;

Sans, S ;

Menotti, A ;

De Backer, G ;

De Bacquer, D ;

Ducimetière, P ;

Jousilahti, P ;

Keil, U ;

Njolstad, I ;

Oganov, RG ;

Thomsen, T ;

Tunstall-Pedoe, H ;

Tverdal, A ;

Wedel, H ;

Whincup, P ;

Wilhelmsen, L ;

Graham, IM .

EUROPEAN HEART JOURNAL, 2003, 24 (11) :987-1003

← 1 2 3 4 →